Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Shares Set to Reverse Split on Monday, October 26th

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD)’s stock is set to reverse split on the morning of Monday, October 26th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Hong Kong Pharma Digital Technology Stock Performance

NASDAQ HKPD opened at $0.10 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.86 and a quick ratio of 3.75. The stock has a 50-day simple moving average of $0.19 and a 200 day simple moving average of $0.39. Hong Kong Pharma Digital Technology has a twelve month low of $0.08 and a twelve month high of $1.72.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.04) EPS for the quarter. The business had revenue of $3.15 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.